Eptinezumab (new indication: prophylaxis of migraine)



  • Active Sustance: Eptinezumab
  • Name: Vyepti®
  • Therapeutic area: Prophylaxis of migraine
  • Pharmaceutical company: Lundbeck GmbH


Time table:

  • Start: 01.09.2022
  • Final decision by G-BA: 16.02.2023


Final decision:

  1. Patients, who are eligible for conventional migraine prophylaxis: No additional benefit proved
  2. Patients, who do not respond to, are not suitable for, or are intolerant of any of the drug therapies/classes of drugs mentioned (metoprolol, propranolol, flunarizine, topiramate, amitriptyline, Clostridium botulinum toxin type A: No additional benefit proved